ANI Pharma Reports First Quarter Results And Year-To-Date 2016 Highlights And Reaffirms Updated Guidance

BAUDETTE, Minn., May 5, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today reported financial results for the three months ended March 31, 2016, and reaffirmed its financial guidance for 2016 as updated on April 4, 2016. The Company will host its earnings conference call this morning, May 5, 2016, at 10:30 AM ET. Investors and other interested parties can join the call by dialing (844) 295-8236. The conference ID is 93601942.

Arthur S. Przybyl, President and CEO, stated,

"ANI had a strong first quarter. Thus far in 2016, we have closed three acquisitions and received two FDA approvals. We anticipate launching a total of seven products in the second quarter of 2016, three of which were launched in April.

We began the year with the completion of our acquisition of the Corticotropin NDAs on January 4^th, followed closely by the January 28^th acquisition of the exclusive rights to distribute the authorized generic of Lipofen®, as well as 1% and 2.5% hydrocortisone rectal cream. We launched the hydrocortisone rectal cream products in April and are currently launching the authorized generic of Lipofen® in our own label. On April 1^st, we completed our acquisition of the Inderal® NDA, which will be accretive to revenue and adjusted non-GAAP EBITDA starting in the second quarter and is included in our guidance."

ANI's Updated Guidance for the Full Year 2016

ANI's estimates are based on projected results for the twelve months ending December 31, 2016 and reflect management's current beliefs about product pricing, prescription trends, inventory levels, cost of sales, operating costs, and the anticipated timing of future product launches and events.

• Net revenues for 2016 to be between $119 million and $134 million.
• Adjusted non-GAAP EBITDA^(a), to be between $55 million and $63 million.
• Adjusted non-GAAP net income per diluted share^(b), to be between $3.54 and $3.91, assuming 11,489 thousand weighted average shares outstanding.
• Reported (US GAAP) diluted EPS to be between $0.30 and $0.65.

ANI's 2016 guidance is based on certain assumptions including:

• EEMT market share is anticipated to remain stable at approximately 50%.
• Cost of sales^(c) of approximately 35%.
• Operating expenses^(d), inclusive of research and development costs, of between $24 and $24.5 million.
• Depreciation and amortization expense of approximately $22.6 million.
• Interest expense of approximately $11.4 million.
• Current tax provision of between $11.5 and $16.5 million.

^(a) See Table 2 for US GAAP reconciliation.
^(b) See Table 3 for US GAAP reconciliation.
^(c) Exclusive of depreciation and amortization.
^(d) Excludes non-cash stock compensation expense.

^(e) Per IMS Health
^(f) FDA's Target Action Date, per FDA communications

Year-to-Date Highlights Include:

• First quarter net revenues of $20.6 million, an increase of 9% as compared to $18.8 million for the same period in 2015.
• First quarter adjusted non-GAAP EBITDA of $11.4 million, a slight decrease of 1% as compared to $11.5 million for the same period in 2015.
• First quarter operating income of $5.7 million, a decrease of 41% as compared to $9.6 million for the same period in 2015.
• First quarter adjusted non-GAAP diluted earnings per share of $0.76.
• First quarter diluted earnings per share of $0.12.
• Appointment of Stephen P. Carey as Vice President and Chief Financial Officer.
• Acquired NDAs for Corticotropin and Corticotropin-Zinc.
• Acquired exclusive rights to distribute an authorized generic of Lipofen® and 1% and 2.5% hydrocortisone rectal cream.
• Acquired the product rights for Inderal® LA.
• Received ANDA approval for Donepezil tablets (via Dexcel partnership).
• Received ANDA approval for Oxycodone capsules.
• Launched 1% and 2.5% hydrocortisone rectal cream.
• Launched Inderal® LA and Propranolol ER.
• Repurchased 65 thousand shares of ANIP common stock for $2.5 million.

For the three months ended March 31, 2016, ANI reported net revenues of $20.6 million, an increase of 9% from $18.8 million in the prior year period, due to the following factors:

• Revenues from sales of generic pharmaceuticals increased 8%, to $13.3 million from $12.3 million in the prior period, primarily due to, sales of Oxycodone oral solution, Vancomycin, Nimodipine, and Flecainide, all of which were launched in Q4 2015, as well as full quarter sales of Etodolac, and Propafenone, which launched in Q1 2015.
• Revenues from sales of branded pharmaceuticals increased 31%, to $5.6 million from $4.3 million in the prior period, primarily as a result of higher sales of Lithobid and Vancocin, partially offset by lower unit sales of Reglan and increased Medicaid utilization for Lithobid and Vancocin.
• Contract manufacturing revenue increased by 15% to $1.4 million from $1.2 million in the prior year period, primarily as a result of the timing of customer orders.
• Contract services and other income decreased by 70%, to $0.3 million from $1.1 million, primarily because the Company launched an authorized generic for Vancocin under its own label, which replaced the authorized generic product previously on the market, partially offset by royalty income on sales of the authorized generic of Lipofen®, which is anticipated to launch under the ANI label in the second quarter.

Cost of sales increased as a percentage of net revenues to 17% from 15%, primarily as a result of increased sales of products with profit-sharing arrangements.  

Research and development costs increased to $1.0 million for the three months ended March 31, 2016, from $0.4 million in the prior year period. The increase was due to timing of work on development projects. Major development projects include the ANDAs acquired in 2014 and 2015, as well as collaborations with partners.

Selling, general, and administrative expenses increased to $5.9 million for the three months ended March 31, 2016, from $4.8 million in the prior year period. The increase was primarily due to increased personnel and compensation costs to support growth of the business.

Net income was $1.3 million for the three months ended March 31, 2016, as compared to net income of $4.4 million in the prior year period, primarily due to a $3.3 million increase in depreciation and amortization in the current period. Diluted earnings per share for the three months ended March 31, 2016 was $0.12, based on 11,489 thousand diluted shares outstanding, as compared to diluted earnings per share of $0.38 in the prior year period.

Adjusted non-GAAP net income per diluted share was $0.76, as compared to adjusted non-GAAP net income per diluted share of $0.71 in the prior year period. For a reconciliation of adjusted non-GAAP net income per diluted share to GAAP net income, please see Table 3.

ANI generated $11.0 million of positive cash flows from operations in the three months ended March 31, 2016. Also in the first quarter, ANI purchased from Merck the NDAs for Corticotropin and Corticotropin-Zinc for $75.0 million and a percentage of future net sales on products sold under the NDAs. ANI also purchased from H2-Pharma, LLC the exclusive U.S. distribution rights for three products, as well as an early stage development project for a generic injectable drug product, for $8.8 million in cash and the assumption of an accrued royalty of $1.2 million.

To read full press release, please click here.